Defunct Company
Total Trials
22
As Lead Sponsor
20
As Collaborator
2
Total Enrollment
8,621
NCT00021697
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
Phase: Phase 3
Role: Lead Sponsor
Start: Jan 31, 2001
Completion: Apr 30, 2002
NCT00050232
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Start: Dec 31, 2002
Completion: Jun 30, 2004
NCT00056524
Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)
Start: Feb 28, 2003
Completion: Jun 30, 2007
NCT00113620
Safety and Efficacy of Dextromethorphan and Quinidine in the Treatment of the Pain of Diabetic Neuropathy
Start: Jul 31, 2005
Completion: Feb 28, 2007
NCT00573443
Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS
Start: Dec 31, 2007
Completion: Sep 30, 2009
NCT01366027
PRISM Registry: Pseudobulbar Affect Registry Series
Phase: N/A
Start: May 31, 2011
Completion: Sep 30, 2012
NCT01324232
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Phase: Phase 2
Start: Sep 8, 2011
Completion: Sep 26, 2013
NCT01584440
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease
Start: Aug 13, 2012
Completion: Jul 30, 2014
NCT01832350
Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease
Phase: Phase 4
Role: Collaborator
Start: Aug 28, 2012
Completion: Dec 1, 2016
NCT01667679
Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura
Start: Aug 31, 2012
Completion: Jun 30, 2014
NCT01787747
Pharmacokinetics (PK) and Tolerability of AVP-786 in Healthy Volunteers
Phase: Phase 1
Start: Oct 31, 2012
Completion: Feb 28, 2013
NCT01799941
Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)
Start: Feb 28, 2013
Completion: May 31, 2015
NCT02174835
A Phase-1 Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 in Healthy Volunteers
Start: Sep 30, 2013
Completion: Nov 30, 2013
NCT01767129
Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients
Start: Oct 16, 2013
Completion: Feb 5, 2015
NCT02336347
A Phase 1 Study Comparing AVP-786 With AVP-923
Start: May 31, 2014
Completion: Mar 31, 2015
NCT02153502
Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
Start: Jul 31, 2014
Completion: Feb 29, 2016
NCT02176018
Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine
Start: Aug 31, 2014
Completion: Mar 31, 2017
NCT02402595
Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts
Start: Mar 31, 2015
Completion: Jul 31, 2015
NCT02477670
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia
Start: Sep 30, 2015
Completion: Jul 21, 2017
NCT02496039
Effectiveness, Safety, and Health-Related Outcomes of NUEDEXTA® in Nursing Home Patients With Pseudobulbar Affect (PBA)
Completion: May 31, 2016
NCT02534038
Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition
Start: Dec 31, 2015
Completion: Oct 3, 2017
NCT03381664
Study to Assess the Bioavailability, Pharmacokinetics, Safety, and Tolerability of AVP-923 in Healthy Adult Participants
Start: Nov 28, 2017
Completion: Jan 30, 2018